Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC): early-phase trial registry
2 of 2 indexed Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC): 2 US clinical trials tracked, 2 recruiting.
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Phanes Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition extrapulmonary-neuroendocrine-carcinoma-ep-nec
OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
NCT05652686
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Molecular Partners
NCT07278479
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Phanes Therapeutics sponsors the most Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) trials on record, review their full trial history before evaluating a specific study. See Phanes Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) condition card totals 2 registered trials; most-linked intervention Paclitaxel.; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.